ZEVRA THERAPEUTICS, INC. Quarterly Debt-to-equity in % from Q3 2015 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Zevra Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2015 to Q2 2024.
  • Zevra Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 194 %, a 302% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 194 +146 +302% Jun 30, 2024
Q1 2024 139 +101 +261% Mar 31, 2024
Q4 2023 105 +80.8 +331% Dec 31, 2023
Q3 2023 72.2 +57.6 +394% Sep 30, 2023
Q2 2023 48.1 +39.2 +440% Jun 30, 2023
Q1 2023 38.5 +33.7 +693% Mar 31, 2023
Q4 2022 24.4 +18.7 +328% Dec 31, 2022
Q3 2022 14.6 -20.1 -58% Sep 30, 2022
Q2 2022 8.92 -183 -95.4% Jun 30, 2022
Q1 2022 4.86 +221 Mar 31, 2022
Q4 2021 5.71 +122 Dec 31, 2021
Q3 2021 34.8 +151 Sep 30, 2021
Q2 2021 192 +308 Jun 30, 2021
Q1 2021 -217 -101 -87.8% Mar 31, 2021
Q4 2020 -117 +1.91 +1.61% Dec 31, 2020
Q3 2020 -116 +8.7 +6.98% Sep 30, 2020
Q2 2020 -116 +8.49 +6.81% Jun 30, 2020
Q1 2020 -115 +15.7 +12% Mar 31, 2020
Q4 2019 -119 +18.9 +13.7% Dec 31, 2019
Q3 2019 -125 +22.1 +15% Sep 30, 2019
Q2 2019 -125 +45.5 +26.7% Jun 30, 2019
Q1 2019 -131 +68.5 +34.3% Mar 31, 2019
Q4 2018 -138 +106 +43.5% Dec 31, 2018
Q3 2018 -147 +160 +52.1% Sep 30, 2018
Q2 2018 -170 +249 +59.4% Jun 30, 2018
Q1 2018 -200 +480 +70.6% Mar 31, 2018
Q4 2017 -243 +855 +77.8% Dec 31, 2017
Q3 2017 -306 +971 +76% Sep 30, 2017
Q2 2017 -419 +912 +68.5% Jun 30, 2017
Q1 2017 -679 +654 +49% Mar 31, 2017
Q4 2016 -1.1K -746 -212% Dec 31, 2016
Q3 2016 -1.28K -1.08K -544% Sep 30, 2016
Q2 2016 -1.33K Jun 30, 2016
Q1 2016 -1.33K Mar 31, 2016
Q4 2015 -352 Dec 31, 2015
Q3 2015 -198 Sep 30, 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.